Faced with plummeting revenue, mounting shareholder lawsuits, and investigations by the U.S. Securities and Exchange Commission (SCAN, 10/11/00) and the Nasdaq stock exchange, Belgian voice recognition technology provider Lernout & Hauspie has filed for
Faced with plummeting revenue, mounting shareholder lawsuits, and investigations by the U.S. Securities and Exchange Commission (SCAN, 10/11/00) and the Nasdaq stock exchange, Belgian voice recognition technology provider Lernout & Hauspie has filed for Chapter 11 bankruptcy protection.
L&H has partnerships and strategic alliances with most PACS and RIS vendors. The firm says it will continue operating as it seeks to reorganize its debt.
The SEC and Nasdaq began investigating L&H earlier this year in relation to questionable accounting practices. The SEC is focusing on L&H's business dealings in Korea and Singapore. Revenue in those areas appeared to be strong last quarter but could turn out to be part of a complicated bundle of investments connected to the FLV Fund, a Belgian venture capital company linked to L&H founders Jo Lernout and Pol Hauspie. n
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.